Statin use and sex-specific stroke outcomes in patients with vascular disease

被引:41
作者
Bushnell, Cheryl D.
Griffin, Jeffrey
Newby, L. Kristin
Goldstein, Larry B.
Mahaffey, Kenneth W.
Graffagnino, Carmelo A.
Harrington, Robert A.
White, Harvey D.
Simes, R. John
Califf, Robert M.
Topol, Eric J.
Easton, J. Donald
机构
[1] Duke Univ, Med Ctr, Dept Med Neurol, Durham, NC 27710 USA
[2] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC 27710 USA
[3] Duke Univ, Med Ctr, Duke Ctr Cerebrovasc Dis, Durham, NC 27710 USA
[4] Auckland City Hosp, Green Lane Cardiovasc Res, Auckland, New Zealand
[5] Natl Hlth & Med Res Council Clin Trials Ctr, Camperdown, NSW, Australia
[6] Case Western Reserve Univ, Cleveland Clin Fdn, Cleveland, OH 44106 USA
[7] Brown Univ, Dept Neurol, Rhode Isl Hosp, Providence, RI 02912 USA
关键词
stroke assessment; stroke outcome;
D O I
10.1161/01.STR.0000221315.60282.ca
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and Purpose - Although statins reduce the risk of stroke in patients with coronary heart disease, possible differing effects of statins on stroke outcomes based on sex remain uncertain. We investigated the relationships between statin use and sex-specific stroke incidence, severity, and mortality. Methods - Data from 3 trials of oral glycoprotein IIb/IIIa inhibitors ( first and second Sibrafiban versus aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary sYndromes [ SYMPHONY] and Blockade of the glycoprotein IIb/IIIa Receptor to Avoid Vascular Occlusion [ BRAVO]) were pooled and stroke outcomes compared among 8191 baseline statin users versus 14 752 nonusers. Time-to-event data were modeled with proportional hazards regression. Stroke severity was assessed retrospectively with the Canadian Neurological Scale ( CNS) based on records with scoreable neurological examinations. Results - A total of 217 subjects had strokes ( 0.95%). Statin users had a lower risk of stroke in unadjusted ( hazard ratio [ HR], 0.69; 95% CI, 0.51 to 0.92) and risk-adjusted models ( HR, 0.72; 95% CI, 0.53 to 0.97). There was no difference in stroke mortality with statin use ( P = 0.8). CNS scores could be assigned to 106 of the subjects, with no difference in severity among statin users and nonusers ( median CNS = 10.5 in users versus CNS = 9.75 in nonusers; P = 0.14). Women had more severe strokes than men ( median CNS = 10.5 in men versus 9.5 in women; Poisson regression P = 0.035). Women had more severe strokes after adjustment for statin use ( P = 0.03) and the combination of statin use, atrial fibrillation, and age ( P = 0.03). Conclusions - In patients included in these clinical trials of oral glycoprotein IIb/IIIa inhibitors, statin use is associated with a reduced risk of stroke but not severity or mortality. Women had more severe strokes than men, a difference that was not explained by baseline characteristics or statin use.
引用
收藏
页码:1427 / 1431
页数:5
相关论文
共 31 条
[1]   Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice [J].
Amin-Hanjani, S ;
Stagliano, NE ;
Yamada, M ;
Huang, PL ;
Liao, JK ;
Moskowitz, MA .
STROKE, 2001, 32 (04) :980-985
[2]   Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [J].
Baigent, C ;
Keech, A ;
Kearney, PM ;
Blackwell, L ;
Buck, G ;
Pollicino, C ;
Kirby, A ;
Sourjina, T ;
Peto, R ;
Collins, R ;
Simes, J .
LANCET, 2005, 366 (9493) :1267-1278
[3]  
Bushnell C, 2006, STROKE, V37, P744
[4]   Statin use and stroke outcomes in the Heart and Estrogen-Progestin Replacement Study (HERS) [J].
Bushnell, CD ;
Newby, LK ;
Goldstein, LB ;
Lin, F ;
Yaffe, K ;
Simon, JA .
NEUROLOGY, 2004, 62 (06) :968-970
[5]   Hormone replacement therapy and ischemic stroke severity in women - A case-control study [J].
Bushnell, CD ;
Samsa, GP ;
Goldstein, LB .
NEUROLOGY, 2001, 56 (10) :1304-1307
[6]  
Byington RP, 2001, CIRCULATION, V103, P387
[7]   Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke [J].
Chen, JL ;
Zhang, ZG ;
Li, Y ;
Wang, Y ;
Wang, L ;
Jiang, H ;
Zhang, CL ;
Lu, M ;
Katakowski, M ;
Feldkamp, CS ;
Chopp, M .
ANNALS OF NEUROLOGY, 2003, 53 (06) :743-751
[8]  
Collins R, 2004, LANCET, V363, P757
[9]  
Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3
[10]   THE CANADIAN NEUROLOGICAL SCALE - VALIDATION AND RELIABILITY ASSESSMENT [J].
COTE, R ;
BATTISTA, RN ;
WOLFSON, C ;
BOUCHER, J ;
ADAM, J ;
HACHINSKI, V .
NEUROLOGY, 1989, 39 (05) :638-643